A Phase 3 interventional study of Clobazam 10 MG Oral Tablet and Acetazolamide 250Mg Tab in Catamenial Epilepsy and Treatment, sponsored by Mazandaran University of Medical Sciences. Recruiting at 1 site in Iran. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Mazandaran University of Medical Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this randomized clinical trial is to evaluate and compare the efficacy and tolerability of intermittent add-on therapy in adult women of childbearing potential (aged 18-45 years) diagnosed with catamenial epilepsy (C1 perimenstrual pattern).
The main questions it aims to answer are:
Does intermittent treatment with clobazam, acetazolamide, or a temporary 25% dose escalation of baseline antiseizure medications (ASMs) significantly reduce seizure frequency during the perimenstrual phase (days -3 to +3) after three consecutive menstrual cycles? What is the comparative tolerability and treatment withdrawal rate due to adverse effects among the three treatment strategies?
Researchers will compare three parallel active intervention arms:
Intermittent oral clobazam (10 mg every 12 hours) on days -5 to +5 of the menstrual cycle.
Intermittent oral acetazolamide (250 mg every 12 hours) on days -5 to +5 of the menstrual cycle.
A 25% dose increase of one of the baseline maintenance ASMs on days -5 to +5 of the menstrual cycle to determine which strategy provides superior seizure control (measured by the proportion of responders achieving ≥50% seizure reduction) with optimal tolerability and minimal adverse events.
Participants will:
Record seizure type and daily frequency in a diary across three baseline consecutive menstrual cycles to confirm C1 catamenial exacerbation prior to randomization.
Take their allocated intermittent study medication (clobazam, acetazolamide, or a 25% increased dose of baseline ASM) every 12 hours from day -5 to day +5 of each menstrual cycle for three consecutive cycles, while continuing their baseline ASMs unchanged.
Maintain a prospective daily seizure log specifically documenting seizure frequency during the perimenstrual window (days -3 to +3).
Attend monthly follow-up visits with a neurologist to report seizure frequency, treatment adherence, and any emergent adverse effects.
1,850 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
This study's planned enrollment of 90 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Browse Epilepsy studies →Mazandaran University of Medical Sciences is the lead sponsor of 23 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of C1 pattern catamenial epilepsy Regular menstrual cycles
Exclusion Criteria:
History of porphyria History of nephrolithiasis History of renal and hepatic disease History of lung disease Alcohol or drug abuse Use of , sex hormone analogues, or sex hormone derivatives Pregnancy and breastfeeding Benzodiazepine use History of reactions to benzodiazepines or sulfonamides Change in the dose, type, or regimen of antiseizure medication(s) within one month prior to enrollment and during the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One clobazam 10 mg tablet every 12 hours for 3 months on days -5 to +5 of the menstrual cycle.
Drug: Clobazam 10 MG Oral Tablet
One acetazolamide 250 mg tablet every 12 hours for 3 months on days -5 to +5 of the menstrual cycle.
Drug: Acetazolamide 250Mg Tab
A 25% increase in the dose of the baseline antiseizure medication for 3 months on days -5 to +5 of the menstrual cycle. If the patient is on polytherapy, the dose of one of the administered antiseizure medications that does not exceed the therapeutic range with a 25% increase will be escalated.
Drug: Antiepileptic
clobazam 10 mg tablet every 12 hours
Acetazolamide 250Mg Tab every 12 hours
A 25% increase in the dose of the baseline antiseizure medication
Treatment efficacy in reducing perimenstrual seizure frequency
responder rate is recorded throughout the study as \>50% seizure reduction (significant improvement), \<50% reduction (partial improvement), or no change (no improvement)
Time frame: at the end of month 3
Treatment withdrawal rate
Drug withdrawal due to adverse drug effects or lack of efficacy
Time frame: at the end of month 3
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.
Of 86 phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 69. This study's planned 20 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetazolamide
Mazandaran University of Medical Sciences